Thomas Stiermaier1,2, Francesco Santoro3, Tobias Graf1,2, Francesca Guastafierro3, Nicola Tarantino3, Luisa De Gennaro4, Pasquale Caldarola4, Matteo Di Biase3, Holger Thiele5, Natale D Brunetti3, Christian Möller1,2, Ingo Eitel6,7. 1. University Heart Center Lübeck, Medical Clinic II (Cardiology/Angiology/Intensive Care Medicine), University Hospital Schleswig-Holstein, Ratzeburger Allee 160, 23538, Lübeck, Germany. 2. German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany. 3. Department of Medical and Surgical Science, University of Foggia, Foggia, Italy. 4. Department of Cardiology, San Paolo Hospital, Bari, Italy. 5. Department of Internal Medicine/Cardiology, Heart Center Leipzig, University Hospital, Leipzig, Germany. 6. University Heart Center Lübeck, Medical Clinic II (Cardiology/Angiology/Intensive Care Medicine), University Hospital Schleswig-Holstein, Ratzeburger Allee 160, 23538, Lübeck, Germany. ingo.eitel@uksh.de. 7. German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany. ingo.eitel@uksh.de.
Abstract
BACKGROUND: Takotsubo syndrome (TTS), a form of acute transient heart failure, has been associated with severe complications and considerable mortality rates. N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) might serve as a marker to identify high-risk patients but has not yet been investigated regarding prognostic implications in TTS. Aim of this study was to determine the short- and long-term prognostic utility of NT-proBNP in patients with TTS. METHODS: The predictive value of admission NT-proBNP was assessed in an international, multicenter study including 177 consecutive TTS patients. Predefined endpoints were 30-day major adverse cardiac events (MACE) consisting of all-cause death, cardiogenic shock, and pulmonary edema as well as long-term mortality in median 2.3 years after the acute event. RESULTS: Stratification according to median admission NT-proBNP (4511 pg/ml) resulted in significantly higher 30-day MACE [22.5 versus 9.1%; odds ratio (OR) 2.90, 95% confidence interval (CI) 1.20-6.99 p = 0.015] and long-term mortality rates [16.3 versus 9.4%; hazard ratio (HR) 2.72, 95% CI 1.13-6.56 p = 0.021] in patients > median. The best admission NT-proBNP cutoffs to predict 30-day MACE and long-term mortality were determined at 5560 and 8178 pg/ml respectively, with subsequent improved risk stratification for short-term MACE (OR 3.61, 95% CI 1.49-8.72; p = 0.003) and long-term mortality (HR 4.40; 95% CI 1.85-10.44, p < 0.001). Multivariate regression analysis identified admission NT-proBNP as an independent predictor of 30-day MACE (p < 0.001) and long-term mortality (p = 0.012). CONCLUSIONS: Admission NT-proBNP is an independent predictor for short- and long-term adverse events in TTS patients and, therefore, a useful marker for risk stratification immediately at presentation.
BACKGROUND:Takotsubo syndrome (TTS), a form of acute transient heart failure, has been associated with severe complications and considerable mortality rates. N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) might serve as a marker to identify high-risk patients but has not yet been investigated regarding prognostic implications in TTS. Aim of this study was to determine the short- and long-term prognostic utility of NT-proBNP in patients with TTS. METHODS: The predictive value of admission NT-proBNP was assessed in an international, multicenter study including 177 consecutive TTS patients. Predefined endpoints were 30-day major adverse cardiac events (MACE) consisting of all-cause death, cardiogenic shock, and pulmonary edema as well as long-term mortality in median 2.3 years after the acute event. RESULTS: Stratification according to median admission NT-proBNP (4511 pg/ml) resulted in significantly higher 30-day MACE [22.5 versus 9.1%; odds ratio (OR) 2.90, 95% confidence interval (CI) 1.20-6.99 p = 0.015] and long-term mortality rates [16.3 versus 9.4%; hazard ratio (HR) 2.72, 95% CI 1.13-6.56 p = 0.021] in patients > median. The best admission NT-proBNP cutoffs to predict 30-day MACE and long-term mortality were determined at 5560 and 8178 pg/ml respectively, with subsequent improved risk stratification for short-term MACE (OR 3.61, 95% CI 1.49-8.72; p = 0.003) and long-term mortality (HR 4.40; 95% CI 1.85-10.44, p < 0.001). Multivariate regression analysis identified admission NT-proBNP as an independent predictor of 30-day MACE (p < 0.001) and long-term mortality (p = 0.012). CONCLUSIONS: Admission NT-proBNP is an independent predictor for short- and long-term adverse events in TTS patients and, therefore, a useful marker for risk stratification immediately at presentation.
Authors: Francesco Santoro; Armando Ferraretti; Francesco Musaico; Luigi Di Martino; Nicola Tarantino; Riccardo Ieva; Matteo Di Biase; Natale Daniele Brunetti Journal: Intern Emerg Med Date: 2016-02-01 Impact factor: 3.397
Authors: Natale Daniele Brunetti; Francesco Santoro; Luisa De Gennaro; Michele Correale; Antonio Gaglione; Matteo Di Biase Journal: Int J Cardiol Date: 2016-04-13 Impact factor: 4.164
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: Milosz Jaguszewski; Julia Osipova; Jelena-Rima Ghadri; Lars Christian Napp; Christian Widera; Jennifer Franke; Marcin Fijalkowski; Radoslaw Nowak; Marta Fijalkowska; Ingo Volkmann; Hugo A Katus; Kai C Wollert; Johann Bauersachs; Paul Erne; Thomas F Lüscher; Thomas Thum; Christian Templin Journal: Eur Heart J Date: 2013-09-17 Impact factor: 29.983
Authors: Wolfgang Dichtl; Noora Tuovinen; Fabian Barbieri; Agne Adukauskaite; Thomas Senoner; Andrea Rubatscher; Florian Hintringer; Christian Siedentopf; Axel Bauer; Elke R Gizewski; Ruth Steiger Journal: Clin Res Cardiol Date: 2020-01-30 Impact factor: 5.460
Authors: Ekaterina S Prokudina; Boris K Kurbatov; Konstantin V Zavadovsky; Alexander V Vrublevsky; Natalia V Naryzhnaya; Yuri B Lishmanov; Leonid N Maslov; Peter R Oeltgen Journal: Curr Cardiol Rev Date: 2021